LABD is a triple leveraged inverse biotech ETF. In plain English, this is a highly leveraged call on biotechs and pharmaceuticals going down if Trump decides to negotiate drug prices.
Due to the leveraged nature of LABD, the risk of loss is high and therefore it is suitable only for aggressive investors. This is a short-term trade, not a long-term investment.
The new buy zone is $11 to $14.52. Please be aware that this ETF can trade in a very wide range. First target is $19.50 to $20. The second target is $26.